Brainsway
BrainsWay Ltd. is a commercial-stage medical device company focused on development, clinical evaluation, and commercialization of noninvasive neuromodulation systems that stimulate deeper and broader brain regions. The company supports multicenter clinical trials, has obtained regulatory clearances in multiple indications, and maintains a global provider network and educational resources for clinicians and patients.
Industries
Nr. of Employees
medium (51-250)
Brainsway
Patents
Products
Deep transcranial magnetic stimulation system
A medical device platform delivering repeated magnetic pulses via helmet-mounted coils to stimulate targeted brain regions for therapeutic neuromodulation.
BrainsWay Deep TMS for Late-Life Depression
The only TMS system FDA-cleared to treat depression among patients ages 68-86 years, utilizing patented H-coil technology to reach deeper brain structures.
Deep TMS H7-coil System
A deep transcranial magnetic stimulation system utilizing a patented H7-coil helmet assembly to safely and effectively alleviate symptoms of obsessive-compulsive disorder by directly reaching broader and deeper brain regions.
BrainsWay Deep TMS for Smoking Addiction
BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) is a safe and effective aid for short-term smoking cessation in adults, utilizing a patented H4 Coil to stimulate neurons in brain structures associated with addiction.
104 System
BrainsWay's innovative 104 System includes a high-performance stimulator, intuitive touchscreen interface, and efficient cooling system, enabling greater ease of use for operators and superior patient comfort.
104 RCT System
BrainsWay's 104 RCT System enables blinded clinical research via a card reader that randomizes selection of sham or Deep TMS stimulation.
Deep transcranial magnetic stimulation system
A medical device platform delivering repeated magnetic pulses via helmet-mounted coils to stimulate targeted brain regions for therapeutic neuromodulation.
BrainsWay Deep TMS for Late-Life Depression
The only TMS system FDA-cleared to treat depression among patients ages 68-86 years, utilizing patented H-coil technology to reach deeper brain structures.
Deep TMS H7-coil System
A deep transcranial magnetic stimulation system utilizing a patented H7-coil helmet assembly to safely and effectively alleviate symptoms of obsessive-compulsive disorder by directly reaching broader and deeper brain regions.
BrainsWay Deep TMS for Smoking Addiction
BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) is a safe and effective aid for short-term smoking cessation in adults, utilizing a patented H4 Coil to stimulate neurons in brain structures associated with addiction.
104 System
BrainsWay's innovative 104 System includes a high-performance stimulator, intuitive touchscreen interface, and efficient cooling system, enabling greater ease of use for operators and superior patient comfort.
104 RCT System
BrainsWay's 104 RCT System enables blinded clinical research via a card reader that randomizes selection of sham or Deep TMS stimulation.
Services
Clinic-delivered electromagnetic stimulation therapy intended to modulate targeted brain regions for treatment of psychiatric indications.
Collaborative trial support, investigator partnerships, and running company-supported multicenter clinical studies across psychiatric, neurological, and addiction indications.
Clinic-delivered electromagnetic stimulation therapy intended to modulate targeted brain regions for treatment of psychiatric indications.
Collaborative trial support, investigator partnerships, and running company-supported multicenter clinical studies across psychiatric, neurological, and addiction indications.
Expertise Areas
- Neuromodulation device development
- Clinical trial management and multicenter RCTs
- Regulatory submissions and device approvals (FDA, CE marking)
- Reimbursement strategy and payer engagement
Key Technologies
- Deep transcranial magnetic stimulation
- Repetitive transcranial magnetic stimulation (rTMS)
- Specialized coil geometries for deep stimulation
- Quantitative electroencephalography (QEEG)
News & Updates
Regulatory clearance for an accelerated protocol of the company's deep transcranial magnetic stimulation therapy for treatment of major depressive disorder.
Publication of a draft LCD by a regional Medicare Administrative Contractor proposing coverage for deep transcranial magnetic stimulation for obsessive-compulsive disorder.
Announcement of an underwritten public offering of American Depositary Shares and stated intended use of proceeds for commercial expansion, R&D, and regulatory matters.
Summary of a prospective multicenter randomized trial examining medial prefrontal cortex stimulation combined with brief exposure for PTSD; published in Biological Psychiatry (2021).
Journal summary reporting that pretreatment parietal beta power (QEEG) and age were associated with response to deep TMS in treatment‑resistant OCD (Clinical EEG and Neuroscience, 2025).
Regulatory clearances cited for major depressive disorder (2013), obsessive‑compulsive disorder (2018), and smoking cessation (2020).
Regulatory clearance for an accelerated protocol of the company's deep transcranial magnetic stimulation therapy for treatment of major depressive disorder.
Publication of a draft LCD by a regional Medicare Administrative Contractor proposing coverage for deep transcranial magnetic stimulation for obsessive-compulsive disorder.
Announcement of an underwritten public offering of American Depositary Shares and stated intended use of proceeds for commercial expansion, R&D, and regulatory matters.
Summary of a prospective multicenter randomized trial examining medial prefrontal cortex stimulation combined with brief exposure for PTSD; published in Biological Psychiatry (2021).
Journal summary reporting that pretreatment parietal beta power (QEEG) and age were associated with response to deep TMS in treatment‑resistant OCD (Clinical EEG and Neuroscience, 2025).
Regulatory clearances cited for major depressive disorder (2013), obsessive‑compulsive disorder (2018), and smoking cessation (2020).